GSK Seeking European Approval for Injectable Lupus Treatment

06:10 EDT 15 Sep 2017 | PharmPro

GSK receives CHMP positive opinion for self-injectable formulation of Benlysta for systemic lupus erythematosus. SLE is the most common form of lupus, a disease producing autoantibodies that can attack almost any system in the body.
Contributed Author: 
GlaxoSmithKline plc

Original Article: GSK Seeking European Approval for Injectable Lupus Treatment


More From BioPortfolio on "GSK Seeking European Approval for Injectable Lupus Treatment"

Quick Search

Relevant Topics

GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Lupus is a complex and poorly understood condition that affects many parts of the body and causes symptoms ranging from mild to life-threatening. There are several types of lupus. The main types are: discoid lupus erythematosus drug-induced lu...